Regeneron Pharmaceuticals Inc vs Victoria's Secret & Co — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Victoria's Secret & Co trades at $76 (market cap $6.26B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 13.3× Victoria's Secret & Co's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| REGN | VSXY | |
|---|---|---|
Market Cap | $83.43B | $6.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $99.97 |
52-Week Low | $555.51 | $25.56 |
Enterprise Value | $78.14B | $8.64B |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Victoria's Secret (VSXY) trades at $78.47, up 3.85% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with a 45.27% ROE and improving cash flow projections. Recent news highlights PINK brand growth and beauty segment acceleration, though the stock faces near-term pressure from sales concerns despite earnings outperformance.
The outlook remains cautiously optimistic with a $97.33 consensus price target representing 24% upside potential. Key opportunities include sustained PINK growth and margin expansion, while risks involve competitive pressures and execution challenges. Analyst consensus leans bullish with 60% buy ratings, but investors should monitor Q3 2026 results for confirmation of the turnaround trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →